Do peptides help with immune support and immune deficiency?
4 peptides are graded for immune support and immune deficiency on this page. The strongest grade is human RCT evidence, for thymosin alpha-1 and thymalin. Each one is weighed against the standard of care below, and the evidence table gives the grade and a note for every peptide.
What is the standard of care for immune support and immune deficiency?
Vaccination on schedule, sleep, nutrition, and physical activity; evaluate recurrent, severe, or unusual infections for primary or secondary immunodeficiency; immunoglobulin replacement and preventive antimicrobials for confirmed antibody deficiency under an immunologist.
Any peptide below should be judged against this baseline, not against doing nothing. Talk to a licensed provider before replacing or adding to an established treatment.
Which peptides have been studied for immune support and immune deficiency?
Ordered by strength of evidence for this use. Grades follow the methodology; each peptide page lists the individual studies.
| Peptide | Evidence for this use | Note |
|---|---|---|
| Thymosin alpha-1 | Evidence: Human RCT evidence | Improved hepatitis B viral response in a 98 patient trial; in severe sepsis (n = 361), 28 day mortality was 26.0% versus 35.0%, which was not statistically significant; FDA placed it in 503A Category 2 in 2023. [1] [2] |
| Thymalin | Evidence: Human RCT evidence | One sparsely reported randomized, placebo-controlled trial in elderly people, from the institute that developed it and never independently replicated, reported lower mortality and fewer acute respiratory illnesses; a 2021 COVID-19 report described a faster fall in inflammatory markers without stating sample size or how patients were assigned; not approved outside Russia. [4] [5] |
| Thymulin | Evidence: Animal-only evidence | Zinc dependent thymic hormone studied mainly in rodents for immune effects; no human immune function study. [7] |
| LL-37 | Evidence: Animal-only evidence | Human antimicrobial peptide with broad lab and animal activity; no human study of injected LL-37 for immunity. [6] |
Head-to-head comparisons
Cost and access
Price ranges, lawful channels, and insurance notes for peptides graded here. State rules are in the legal guides by state.
Frequently asked questions
Which peptide has the strongest evidence for immune support and immune deficiency?
Thymosin alpha-1 and thymalin have the strongest evidence among the peptides graded here, at human RCT evidence. Thymosin alpha-1: Improved hepatitis B viral response in a 98 patient trial; in severe sepsis (n = 361), 28 day mortality was 26.0% versus 35.0%, which was not statistically significant; FDA placed it in 503A Category 2 in 2023. Thymalin: One sparsely reported randomized, placebo-controlled trial in elderly people, from the institute that developed it and never independently replicated, reported lower mortality and fewer acute respiratory illnesses; a 2021 COVID-19 report described a faster fall in inflammatory markers without stating sample size or how patients were assigned; not approved outside Russia. [1] [2] [4] [5]
Is any peptide FDA approved for immune support and immune deficiency?
No. None of the peptides graded for immune support and immune deficiency is an FDA approved drug, so any use is outside an approved label and depends on the compounding and research status shown on each peptide page. [8]
Has any peptide been tested in a randomized trial for immune support and immune deficiency?
Yes, for Thymosin alpha-1 and thymalin. Check each note for the population and endpoints: a randomized trial in a related group or on a surrogate marker is weaker than one on the outcome you care about. [1] [2] [4] [5]
From the blog
- Thymosin alpha-1 benefits and side effects: the evidence
What randomized trials of thymosin alpha-1 showed in hepatitis B, sepsis, COVID-19, and vaccine response, which side effects they recorded, and where wellness claims outrun the data.
- Thymosin alpha-1 access: approved abroad, not in the US
Thymosin alpha-1 is approved as Zadaxin in more than 30 countries but has never been FDA approved, and it is not on the 503A bulks list. What that means for access, forms, and thymalin.
Sources
- [1]Efficacy of thymosin alpha1 in patients with chronic hepatitis B: a randomized, controlled trialPubMed 9581695, 1998
- [2]The efficacy of thymosin alpha 1 for severe sepsis (ETASS): a multicenter, single-blind, randomized and controlled trialPubMed 23327199, 2013
- [3]Historical review of thymosin alpha 1 in infectious diseasesPubMed 26098768, 2015
- [4]Peptides of pineal gland and thymus prolong human lifePubMed 14523363, 2003
- [5]Results and prospects of using activator of hematopoietic stem cell differentiation in complex therapy for patients with COVID-19PubMed 33575961, 2021
- [6]A comprehensive summary of LL-37, the factotum human cathelicidin peptidePubMed 23246832, 2012
- [7]Contribution of zinc and other metals to the biological activity of the serum thymic factorPubMed 6957870, 1982
- [8]Drugs@FDA: FDA-approved drugs databaseFDA